EUVIMEDEUVIMED entdecken
Open Access

Evaluation of bivalirudin based anticoagulation for extracorporeal membrane oxygenation including patients with COVID-19

Miranda Raguindin iD, Casey Bardsley, Chelsea Bast, David Sugrue, Hasan Kazmi iD, Ashley Milkovits iD

The Journal of ExtraCorporeal Technology · 2025

DOI: 10.1051/ject/2025045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of ExtraCorporeal Technology, 2025. Verfasst von Miranda Raguindin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Carilion Roanoke Memorial Hospital, Roanoke, VA 24014, USA - Hartford Hospital, Hartford, CT 06106, USA. Hauptthemen laut MEDLINE: Extracorporeal Membrane Oxygenation, Hirudins, Peptide Fragments, COVID-19. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although unfractionated heparin (UFH) has traditionally been used for anticoagulation during extracorporeal membrane oxygenation (ECMO), bivalirudin may be preferred due to fewer complications. A prior medication use evaluation of ECMO patients who received bivalirudin resulted in dosing updates to our pharmacist-directed bivalirudin protocol. The intent of this study was to evaluate the efficacy and safety of bivalirudin for anticoagulation during ECMO support post protocol initiation.

Methods

This was a retrospective, single-center, quasi-experimental, pre-post study. Adult patients requiring ECMO support for at least 24 hours and who received bivalirudin between January 1, 2015 to July 31, 2018 (pre-group) and May 1, 2019 to June 30, 2021 (post-group) were included.

Results

There were 38 patients in the pre- and 35 patients in the post-group. The primary outcome, median time to two consecutive activated partial thromboplastin times (aPTTs) within therapeutic range for the initial goal range, was 8.9 hours in the pre- and 14.2 hours in the post-group (p=0.517). In a subgroup analysis of the post-group, the primary outcome was higher in patients with COVID-19 (26.5 vs. 8.6 hours, p=0.018). The median number of dose adjustments to achieve goal aPTT was higher in COVID-19 patients (4 vs. 2, p=0.017).

Conclusion

These results suggest that a standardized pharmacist-directed protocol for bivalirudin in ECMO achieves timely therapeutic anticoagulation levels. Patients with COVID-19 trended toward longer times to two consecutive therapeutic aPTTs. Further studies are needed evaluating dosing strategies in patients with and without COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracorporeal Membrane OxygenationHirudinsPeptide FragmentsCOVID-19AnticoagulantsAntithrombinsHumansRecombinant ProteinsFemaleRetrospective StudiesMaleMiddle AgedAdultPartial Thromboplastin TimeTreatment OutcomeAged

Stichwörter der Autor:innen

Acute respiratory distress syndrome (ARDS)BivalirudinCOVID-19ECMO (extracorporeal membrane oxygenation)Pharmacology

Substanzen

bivalirudinHirudinsRecombinant ProteinsPeptide FragmentsAnticoagulantsAntithrombins

Autor:innen und Institutionen

  • Carilion Roanoke Memorial Hospital, Roanoke, VA 24014, USA - Hartford Hospital, Hartford, CT 06106, USA.
  • Carilion Roanoke Memorial Hospital, Roanoke, VA 24014, USA - North Florida Regional Medical Center, Gainesville, FL 32605, USA.
  • Carilion Roanoke Memorial Hospital, Roanoke, VA 24014, USA - Sentara Virginia Beach General Hospital, Virginia Beach, VA 23454, USA.
  • Carilion Roanoke Memorial Hospital, Roanoke, VA 24014, USA - Duke Raleigh Hospital, Raleigh, NC 27609, USA.
  • Carilion Roanoke Memorial Hospital, Roanoke, VA 24014, USA.

ORCID-Profile: Miranda Raguindin, Hasan Kazmi, Ashley Milkovits

Zitieren

APA

Raguindin, M., Bardsley, C., Bast, C., Sugrue, D., Kazmi, H., & Milkovits, A. (2025). Evaluation of bivalirudin based anticoagulation for extracorporeal membrane oxygenation including patients with COVID-19. The Journal of ExtraCorporeal Technology. https://doi.org/10.1051/ject/2025045

Vancouver

Raguindin M, Bardsley C, Bast C, Sugrue D, Kazmi H, Milkovits A. Evaluation of bivalirudin based anticoagulation for extracorporeal membrane oxygenation including patients with COVID-19. The Journal of ExtraCorporeal Technology. 2025. doi:10.1051/ject/2025045

BibTeX
@article{Raguindin2025,
  author = {Raguindin, Miranda and Bardsley, Casey and Bast, Chelsea and Sugrue, David and Kazmi, Hasan and Milkovits, Ashley},
  title = {Evaluation of bivalirudin based anticoagulation for extracorporeal membrane oxygenation including patients with COVID-19},
  journal = {The Journal of ExtraCorporeal Technology},
  year = {2025},
  doi = {10.1051/ject/2025045}
}
Kostenlos starten →